X4 Pharmaceuticals, Inc.
XFOR
$3.18
$0.3813.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.97M | 28.81M | 1.43M | 560.00K | 563.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.97M | 28.81M | 1.43M | 560.00K | 563.00K |
| Cost of Revenue | 326.00K | 4.72M | 302.00K | 227.00K | 268.00K |
| Gross Profit | 1.65M | 24.09M | 1.13M | 333.00K | 295.00K |
| SG&A Expenses | 9.53M | 15.02M | 15.15M | 15.66M | 13.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.21M | 38.25M | 37.15M | 35.06M | 34.46M |
| Operating Income | -26.23M | -9.44M | -35.72M | -34.50M | -33.90M |
| Income Before Tax | -25.70M | 316.00K | -39.56M | -36.68M | 90.85M |
| Income Tax Expenses | 37.00K | 34.00K | 258.00K | 15.00K | 18.00K |
| Earnings from Continuing Operations | -25.74M | 282.00K | -39.82M | -36.70M | 90.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.74M | 282.00K | -39.82M | -36.70M | 90.83M |
| EBIT | -26.23M | -9.44M | -35.72M | -34.50M | -33.90M |
| EBITDA | -25.88M | -8.97M | -35.44M | -34.23M | -33.70M |
| EPS Basic | -3.47 | 0.04 | -5.89 | -5.48 | 13.60 |
| Normalized Basic EPS | -2.17 | 0.03 | -3.66 | -3.42 | -1.32 |
| EPS Diluted | -3.47 | 0.04 | -5.89 | -5.48 | 13.57 |
| Normalized Diluted EPS | -2.17 | 0.03 | -3.66 | -3.42 | -1.32 |
| Average Basic Shares Outstanding | 7.41M | 6.84M | 6.76M | 6.70M | 6.68M |
| Average Diluted Shares Outstanding | 7.41M | 6.87M | 6.76M | 6.70M | 6.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |